BRIUMVI
BRIUMVI (ublituximab-xiiy) is an anti-CD20 monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The medication works by selectively targeting CD20-expressing B cells, a key driver of abnormal immune activity in MS.
Each preservative-free single-dose vial contains 150 mg of ublituximab-xiiy in 6 mL solution for intravenous infusion after dilution. Administration must be performed by qualified healthcare professionals in an appropriate clinical setting.
InfusionMed USA, based in Carrollton, Texas, supplies BRIUMVI to licensed infusion centers and specialty pharmacies across Dallas, Frisco, McKinney, Plano, and North Texas, ensuring strict cold-chain handling and FDA-compliant distribution.
For professional use only. Store refrigerated at 2°C–8°C (36°F–46°F). Do not freeze or shake.
Download Form